Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant vs glimepiride for glycemic control in overweight/obese type 2 diabetes patients on metformin
2006-005385-39Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in type 2 diabetes mellitus (T2DM), obesity and Overweight (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c at 52 weeks. Started May 2007; status: completed.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on 2006-005385-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005385-39.